Empyrean Therapeutics, Inc., a leading biopharmaceutical enterprise, revealed the acquisition of a cutting-edge TLR-2 antagonist molecule from Eos Therapies, Inc., marking a key strategic initiative. This acquisition is poised to fast-track the creation of a groundbreaking cancer medication targeting challenging cancers, such as those of the brain, pancreas, and breast. Currently in the pre-investigatory new drug (pre-IND) stage, the molecule, named EMS-312, is being prepared for comprehensive in vivo validation. Empyrean is set to capitalize on its advanced research infrastructure and distinguished global network to hasten the molecule’s journey into human clinical trials and subsequent commercial launch.
“This acquisition is a monumental achievement for Empyrean Therapeutics,” expressed Kal Fishman, CEO of Empyrean Therapeutics. “The EMS-312 molecule shows remarkable target affinity, high potency, promising drug-like traits, bioavailability when taken orally, brain penetration, and it circumvents efflux pumps, meeting our lead criteria. We are eager to incorporate it into our development pipeline and are resolute in pushing it rapidly through developmental stages. Our ambition is to bring hope to patients globally struggling with some of the most challenging cancer types.”
Doug Bonhaus, PhD, CEO of Eos Therapies, commented, “We are delighted about the completion of this transaction with Empyrean Therapeutics, and are excited to witness the advancement of this promising molecule as a potential pioneering treatment for cancer.”
The transfer was finalized in October 2024, with the EMS-312 molecule newly patented across all major markets. Both organizations are collaborating closely to ensure the seamless transition of intellectual property, relevant research data, and compound materials to Empyrean’s laboratories located at the Center for Novel Therapeutics in La Jolla, California.
Empyrean Therapeutics, Inc. is committed to revolutionizing cancer treatment through the development of transformative therapies, with a mission to employ cutting-edge science to deliver life-altering medications to patients contending with the most aggressive types of cancer.
Situated in San Diego, Eos Therapies specializes in the discovery and clinical development of small molecule Toll-Like Receptor (TLR) antagonists aimed at treating Parkinson’s disease and other neurodegenerative conditions.